Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01240252 · ClinicalTrials.gov registry record · Phase 1
Insulin Receptor Substrate 1 (IRS-1) Regulation in Insulin Resistance
A Phase 1 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
NCT01240252: Completed Phase 1 study, sponsored by Mayo Clinic.
NCT01240252 is a Phase 1 study that has completed, run by Mayo Clinic. The registered enrollment target is 14 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01240252, a Phase 1 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
Study Summary
The study is being conducted to find out why too much fat in your blood stream may cause insulin resistance in your muscles. Insulin is the hormone, produced normally by your body, which causes your blood sugar to return to normal after you eat.
Interventions
- DRUG Human insulin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2012-03 |
| Est. Completion | 2012-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01240252
The ClinicalTrials.gov registry entry for NCT01240252 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Human insulin is the first listed.
NCT01240252 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01240252 about?
NCT01240252 is a clinical study titled "Insulin Receptor Substrate 1 (IRS-1) Regulation in Insulin Resistance". The study is being conducted to find out why too much fat in your blood stream may cause insulin resistance in your muscles. Insulin is the hormone, produced normally by your body, which causes your blood sugar to return to normal after you eat.
What is the current status of trial NCT01240252?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2012-03. Estimated completion is 2012-07.
What interventions are being tested in trial NCT01240252?
The interventions under investigation include: Human insulin (DRUG).
Who is sponsoring clinical trial NCT01240252?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.